Rescue Study Expertise for At-Risk Clinical Trials When clinical studies face enrollment shortfalls, startup delays, operational challenges, or CRO underperformance, sponsors need more than additional resources. They need an experienced partner c...
How Strategic Site Engagement and Patient-Centric Retention Supported Study Success A Phase II Alzheimer's disease study evaluating an investigational therapy faced significant operational challenges, including a complex biomarker-driven design r...
Parkinson’s Disease CRO Expertise for Complex Clinical Trials As Parkinson’s disease research advances toward earlier intervention, disease modification, and prevention-focused approaches, sponsors need a partner with deep therapeutic experti...
As the search for reliable biomarkers in neurodegenerative diseases continues, researchers are working to better understand how disease-related proteins can support diagnosis, monitoring, and future treatment development. A newly published study i...
LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis: A Post-hoc Analysis of the FRANCIS Randomized Trial Patients with rheumatoid arthritis (RA) face an increased risk of cardiovascular disease, driven by a complex in...
MASH CRO Expertise for Complex Clinical Trials As MASH clinical development continues to evolve, sponsors face increasing challenges in patient identification, complex eligibility criteria, high screening failure rates, and competition for experi...
How a Site-Centric Delivery Model Accelerated Study Start-Up When a Phase II Parkinson’s disease study faced aggressive start-up and enrollment targets, the study team was tasked with achieving first patient consent within just eight weeks of f...
Comparing FIB-4 and MAF-5 for Advanced Fibrosis Screening in Primary Care Complete the form to access the poster and explore the preliminary GRIPonMASH findings. [gravityform id="19" title="false"] As the prevalence of MASLD and MASH contin...
Alzheimer's Disease CRO Expertise for Complex Clinical Trials As Alzheimer's research shifts toward earlier intervention and biomarker-defined populations, sponsors need more than operational support. They need a partner who understands the scien...
Ensuring that Alzheimer’s disease (AD) clinical trials reflect real-world patient populations remains a key challenge, as eligibility criteria can unintentionally influence who is able to participate. A recent study published in The Journal of P...
"*" indicates required fields
"*" indicates required fields
